Skip to main content
. Author manuscript; available in PMC: 2015 Jul 28.
Published in final edited form as: J Cancer Ther. 2011 Mar 31;2(1):22–39. doi: 10.4236/jct.2011.21004

Figure 6.

Figure 6

Influence of selenium on the potency of covalent epirubicin-(C13-imino)-[anti-HER2/neu] immunochemotherapeutic against chemotherapeutic-resistant SKBr-3 mammary carcinoma. Legend: (◆) covalent epirubicin-(C13-imino)-[anti-HER2/neu] immunochemotherapeutic, and (∎) covalent epirubicin-(C13-imino)-[anti-HER2/neu] immuno-chemotherapeutic with selenium (5 mM). Monolayers of SKBr-3 mammary carcinoma were incubated for 72-hours and cytotoxicity measured as a function of MTT cell vitality relative to matched negative reference controls.